6533b86efe1ef96bd12cb2ce

RESEARCH PRODUCT

Osteoradionecrosis and Antiresorptive Drug-Related Osteonecrosis of the Jaws

Bilal Al-nawasPit Jacob Voss

subject

OncologyDrugmedicine.medical_specialtyTreatment regimenbusiness.industryOsteoradionecrosismedicine.medical_treatmentmedia_common.quotation_subjectmedicine.diseaseRadiation therapyDenosumabSupportive psychotherapyInternal medicinemedicineIn patientOsteonecrosis of the jawbusinessmedia_commonmedicine.drug

description

With similar clinical appearances, osteoradionecrosis and antiresorptive drug-related osteonecrosis of the jaw (ARONJ) are different side effects of treatment regimens of mostly malignant diseases. While radiotherapy is usually used to control the progress of locoregional tumors, antiresorptive agents are administered in patients with generalized catabolic bone diseases. Although surgical techniques to treat both diseases are comparable, it should be noted that the pathophysiology is different. For the different genesis of both entities, they are dealt with separately in the following chapter.

yearjournalcountryeditionlanguage
2019-01-01
https://doi.org/10.1007/978-1-4939-1529-3_9